Skip to content
The Nexus
DossierENTITY

RXRX

Coverage of RXRX in the Nexus archive.

Earliest in view: Aug 5 · 10:42 UTCMost recent: Aug 5 · 10:42 UTC
Co-mentioned in this coverage
Recursion Pharmaceuticals Inc.organization1Zacks Investment Researchorganization1Automated Insightsorganization1
Recent coverage
  • BUSINESSAug 5 · 10:42 UTCWTOP DC
    Recursion Pharmaceuticals: Q2 Earnings Snapshot

    Recursion Pharmaceuticals Inc. (RXRX) reported a second-quarter loss of $131 million, or 25 cents per share, exceeding Wall Street expectations of a 23-cent loss. The company's revenue of $7.7 million also fell short of analyst projections of $14.4 million.

RXRX · Dossier · The Nexus